MedPath

The Role of Partial Hydrolyzed Guar Gum in High Stoma Output Management Among Cancer Patients With Ileostomy

Not Applicable
Completed
Conditions
Rectal Cancer
Registration Number
NCT04678349
Lead Sponsor
Universiti Putra Malaysia
Brief Summary

this is a cross sectional intervention study to investigate the role of partial hydrolyzed guar gum in high stoma output management among cancer patients with ileostomy. This study hypotheses there is improvement in stoma output in PHGG if compare with control. There are two groups of subjects in this study. Conventional group (CG) will include retrospective historical data (those subjects with post-operative ileostomy) from Jan 2016 to June 2019. Intervention group (PHGG) will be subjects with ileostomy which involves prospective intervention by giving partial hydrolyzed guar gum upon start orally. Data on stoma output (volume \& consistency), length of hospital stay, readmission within 30-days discharged and dietary intake will be recorded in data collection form.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
29
Inclusion Criteria
  • Cancer patients with ileostomy
  • At least 18 years of age
  • Malaysian
Exclusion Criteria
  • Not cancer patients with ileostomy
  • Patients who participate in other study at the same time
  • Vulnerable subjects
  • Palliative patients
  • Patient has fistula

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
ileostomy stoma outputup to 1 month

volume (ml)

Secondary Outcome Measures
NameTimeMethod
Length of hospital stayup to 1 month

days of hospital stays

Readmission within 30-days dischargedup to 1 month

readmit to ward due to complications after discharge

dietary intakeup to 1 month

protein intake (g/day)

Dietary intakeup to 1 month

energy (kcal/day)

Trial Locations

Locations (1)

National Cancer Institute

🇲🇾

Putrajaya, Malaysia

National Cancer Institute
🇲🇾Putrajaya, Malaysia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.